Residency · Residency · Medicine Pediatrics
Urinary Tract Infections Across Ages
Overview
UTIs are among the most common bacterial infections across the lifespan. Epidemiology shifts by age and sex: male predominance in neonates (uncircumcised), female predominance from childhood onward. Pediatric UTIs carry unique considerations around imaging, vesicoureteral reflux, and renal scarring. Adult UTIs focus on distinguishing uncomplicated from complicated infections, catheter-associated UTI, and antibiotic stewardship.
Epidemiology
Pediatric
Prevalence of UTI in febrile infants: ~5-7% overall; higher in uncircumcised males <6 months (~20%) and white females <2 years (~16%) After age 1, female predominance emerges (8:1 ratio) Risk factors: female sex, uncircumcised males, vesicoureteral reflux (VUR), posterior urethral valves, dysfunctional voiding, constipation, neurogenic bladder.
Adult
Women: 50-60% lifetime risk; peak incidence in sexually active young women and postmenopausal women. Men: uncommon until age >50 (prostate enlargement); UTI in young men warrants evaluation for structural abnormality. Recurrent UTI: >= 2 UTIs in 6 months or >= 3 in 12 months; affects ~25% of women. Catheter-associated UTI (CAUTI): most common healthcare-associated infection.
Microbiology
E. coli: dominant pathogen across all ages (70-90% of uncomplicated UTIs) Klebsiella: second most common, especially in neonates. Proteus mirabilis: more common in uncircumcised males; associated with struvite stones. Enterococcus: more common in catheterized patients and recent antibiotic use. Staphylococcus saprophyticus: young sexually active women (second most common in this group) Group B Streptococcus: neonatal UTI, pregnant women. Pseudomonas: catheterized patients, structural urinary tract abnormalities. Increasing fluoroquinolone and TMP-SMX resistance in E. coli is a global concern; local antibiogram is essential.
Clinical Presentation
Neonates and Infants (<2 years)
Nonspecific: fever (may be the only sign), irritability, poor feeding, vomiting, failure to thrive. No localizing urinary symptoms at this age. Jaundice in neonates can be the presenting sign of UTI (especially E. coli) Sepsis workup in febrile neonates <60 days must include urine culture.
Preschool Children (2-5 years)
Fever, abdominal pain, vomiting. May report dysuria, frequency, urgency, new-onset incontinence. Malodorous urine is often reported but is not specific.
School-Age Children and Adolescents
Classic symptoms: dysuria, frequency, urgency, suprapubic pain. Pyelonephritis: high fever (>39C), flank pain, vomiting, ill appearance. Adolescent females: must distinguish from STI (urethritis, vaginitis)
Adults
Uncomplicated cystitis: dysuria, frequency, urgency, suprapubic pain; no systemic symptoms. Pyelonephritis: fever, flank pain, costovertebral angle tenderness, nausea/vomiting; may have concurrent cystitis symptoms. Complicated UTI: any UTI in men, pregnant women, patients with structural abnormalities, indwelling catheter, immunosuppression, or renal transplant. Elderly: may present atypically with altered mental status, functional decline; however, asymptomatic bacteriuria is extremely common and should NOT be treated (except in pregnancy)
<image>Clinical presentation spectrum of UTI by age group from neonate through elderly adult showing the shift from nonspecific systemic symptoms to classic localized urinary symptoms with age</image>
Diagnosis
Urine Collection Methods
Suprapubic aspiration: gold standard in neonates; any growth is significant. Catheterization: preferred for non-toilet-trained children; >50,000 CFU/mL is significant. Clean-catch midstream: for toilet-trained children and adults; >100,000 CFU/mL is classic threshold. Bag specimen: high false-positive rate (85%); useful ONLY if negative (to exclude UTI); positive bag specimen should be confirmed by catheterization or SPA.
Urinalysis
Dipstick: leukocyte esterase (sensitivity ~83%) and nitrite (specific but insensitive ~53%, especially in children — bacteria need time in bladder to convert nitrate) Microscopy: pyuria (>5 WBC/HPF) and bacteriuria. Urinalysis alone cannot confirm or exclude UTI in young children — culture is mandatory. In adults, classic uncomplicated cystitis can be treated empirically based on symptoms alone without culture (AUA/IDSA guidelines)
Urine Culture
Required for all children <2 years with suspected UTI. Required for pyelonephritis, complicated UTI, recurrent UTI, and treatment failure at any age. Not required for uncomplicated cystitis in adult women (empiric treatment appropriate) Obtain BEFORE antibiotics whenever possible.
Management
Pediatric UTI Treatment
Febrile UTI / pyelonephritis: Oral antibiotics are equivalent to IV for most children >2 months who can tolerate PO and are not toxic-appearing. Oral options: cephalexin, cefixime, amoxicillin-clavulanate (7-14 day course) IV options (for toxic/septic or unable to tolerate PO): ceftriaxone, ampicillin + gentamicin (neonates) Duration: 7-14 days for pyelonephritis. Afebrile UTI / cystitis (older children): TMP-SMX, nitrofurantoin, cephalexin. Duration: 3-5 days for uncomplicated cystitis.
Adult UTI Treatment
| Infection Type | First-Line Agent | Duration |
|---|---|---|
| Uncomplicated cystitis | Nitrofurantoin 100 mg BID | 5 days |
| Uncomplicated cystitis | TMP-SMX DS BID (if resistance <20%) | 3 days |
| Uncomplicated cystitis | Fosfomycin 3 g | Single dose |
| Pyelonephritis (outpatient) | Ciprofloxacin 500 mg BID | 7 days |
| Pyelonephritis (inpatient) | IV ceftriaxone, then PO step-down | 10-14 days |
| Complicated UTI | Broad-spectrum empiric + imaging | 10-14 days |
| CAUTI (symptomatic) | Based on culture; remove/replace catheter | 7-14 days |
Uncomplicated cystitis (non-pregnant women): Second-line: beta-lactams (less effective), fluoroquinolones (reserve for complicated UTI) Acute pyelonephritis: Outpatient (mild): ciprofloxacin 500 mg BID x 7 days, or TMP-SMX x 14 days (with initial IV ceftriaxone dose) Inpatient (severe): IV ceftriaxone, fluoroquinolone, or piperacillin-tazobactam; step down to PO based on susceptibilities. Complicated UTI: broader-spectrum empiric therapy; 10-14 days; imaging to identify obstructing stone, abscess. CAUTI: remove or replace catheter; treat only if symptomatic; 7-day course for prompt resolution, 10-14 days for delayed response.
Asymptomatic Bacteriuria
Treat only in: pregnancy (reduces pyelonephritis risk) and before urologic procedures. Do NOT treat: elderly (even in nursing homes), diabetics, catheterized patients, spinal cord injury — treatment does not improve outcomes and promotes resistance.
<image>Antibiotic selection flowchart for UTI by age group and infection type showing first-line and alternative agents with recommended durations for uncomplicated cystitis, pyelonephritis, and complicated UTI</image>
Imaging After Pediatric UTI
AAP 2011 Guidelines (Ages 2-24 months)
Renal and bladder ultrasound (RBUS): recommended after first febrile UTI in all children 2-24 months. Voiding cystourethrogram (VCUG): NOT routinely recommended after first febrile UTI. VCUG indications: abnormal RBUS (hydronephrosis, scarring, high-grade reflux findings), recurrent febrile UTI, atypical clinical course.
The RIVUR Trial and VUR Management
Vesicoureteral reflux (VUR): retrograde flow of urine from bladder to ureter/kidney. Grading I-V based on VCUG appearance. RIVUR trial: daily TMP-SMX prophylaxis reduced UTI recurrence by 50% in children with grades I-IV VUR but did not prevent renal scarring. Low-grade VUR (I-II): high spontaneous resolution rate; observation preferred. High-grade VUR (IV-V): consider surgical correction (ureteral reimplantation or endoscopic injection of Deflux) Antibiotic prophylaxis: ongoing debate; trend toward selective use in higher-grade reflux. Bowel-bladder dysfunction (constipation, dysfunctional voiding) must be addressed concurrently — major contributor to recurrent UTI.
DMSA Renal Scan
Gold standard for detecting renal scarring. Acute DMSA: can identify pyelonephritis (photopenic areas) Follow-up DMSA (4-6 months after UTI): identifies permanent cortical scarring. Renal scarring increases risk of hypertension, proteinuria, and CKD in adulthood.
Recurrent UTI in Adults
Evaluation
Urinalysis and culture to confirm true infections (not just symptoms) Consider: voiding habits, fluid intake, post-coital voiding, contraceptive method (spermicides increase risk) Imaging/cystoscopy generally NOT needed for uncomplicated recurrent cystitis in premenopausal women. Men with recurrent UTI: evaluate for prostatic enlargement, urethral stricture, stones.
Prevention Strategies
Behavioral: adequate hydration, timed voiding, post-coital voiding, avoid spermicides. Vaginal estrogen: effective in postmenopausal women (RR reduction ~50%); cream, ring, or tablet. Antibiotic prophylaxis: continuous low-dose (nitrofurantoin 50-100 mg nightly, TMP-SMX half-tab nightly) or post-coital (single dose) Self-start therapy: patient-initiated 3-day antibiotic course at symptom onset. Cranberry products: modest evidence for prevention; NNT ~12-15. D-mannose: promising but limited evidence. Methenamine hippurate: emerging evidence supports non-inferiority to antibiotics for prophylaxis.
<image>Grading system for vesicoureteral reflux on VCUG showing grades I through V with associated spontaneous resolution rates and management recommendations</image>
UTI in Pregnancy
Screen all pregnant women for asymptomatic bacteriuria at first prenatal visit (12-16 weeks) Untreated bacteriuria progresses to pyelonephritis in 20-40% of pregnant women. Safe antibiotics: amoxicillin, cephalosporins, nitrofurantoin (avoid in first trimester and near term), fosfomycin. Avoid: fluoroquinolones (cartilage toxicity), TMP-SMX (first trimester — folate antagonism; third trimester — kernicterus risk) Pyelonephritis in pregnancy: inpatient IV antibiotics initially; high risk of preterm labor, sepsis.
Clinical Pearls
In a febrile infant <2 months without a clear source, UTI must be excluded with catheterized urine culture — do not rely on bag specimens. Circumcision reduces UTI risk by ~90% in male infants; the NNT to prevent one UTI is ~10 for high-risk (recurrent UTI, VUR) and ~100 for average-risk boys. Constipation is the most underappreciated contributor to recurrent UTI in children — always assess and treat. Do NOT treat asymptomatic bacteriuria in the elderly — it is almost never the cause of altered mental status and treatment increases antibiotic resistance. Nitrofurantoin does not achieve adequate tissue levels for pyelonephritis — use only for lower UTI. In young women with classic cystitis symptoms, empiric treatment without culture is appropriate and cost-effective. UTI in a male aged 15-50 is unusual and warrants investigation for anatomic abnormality or STI.
References
- Subcommittee on Urinary Tract Infection. Reaffirmation of AAP Clinical Practice Guideline: Diagnosis and Management of the Initial UTI in Febrile Infants and Young Children 2-24 Months of Age. Pediatrics. 2016;138(6):e20163026.
- RIVUR Trial Investigators. Antimicrobial Prophylaxis for Children with Vesicoureteral Reflux. N Engl J Med. 2014;370(25):2367-2376.
- Gupta K, Hooton TM, Naber KG, et al. International Clinical Practice Guidelines for the Treatment of Acute Uncomplicated Cystitis and Pyelonephritis in Women. Clin Infect Dis. 2011;52(5):e103-e120.
- Nicolle LE, Gupta K, Bradley SF, et al. Clinical Practice Guideline for the Management of Asymptomatic Bacteriuria: 2019 Update by IDSA. Clin Infect Dis. 2019;68(10):e83-e110.
